Biopharma Leads Pharma Prescription 
Pharmaceutical Technology
SEPTEMBER 8, 2022
The speciality drug channel participants, including speciality pharmacies, biopharma companies, and distributors, are transforming their operations with automated and secure data systems and next-generation analytics, which will improve data collection, partner performance and strategy effectiveness. Prescription refill and renewal.
pharmaphorum
DECEMBER 18, 2022
Uniquely positioned, traditional patient access hubs promise to simplify the process of getting patients started on therapy and offer to provide HCPs with much-needed assistance in navigating payer requirements leading up to therapy starts. However, the cumbersome hub workflow overshadows the purported gains in productivity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
AUGUST 8, 2023
The biopharma industry is sweating the long-term implications and warning that it could mean less lifesaving drugs make it to patients going forward. The law was top-of-mind at this summer’s ASCO and BIO meetings, tentpole events in the biopharma conference calendar. R&D efficiency is more critical than ever.
pharmaphorum
DECEMBER 23, 2022
With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”.
Pharmaceutical Technology
NOVEMBER 4, 2022
As visibility diminishes, mismanagement of the supply chain can not only lead to revenue and reputational damage for manufacturers but more importantly, loss of life for patients. For example, digital twins of pharmaceutical supply chains can predict bottlenecks and give suggestions for how to respond using prescriptive AI.
Clarivate
OCTOBER 25, 2023
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization. With 27.5%
Clarivate
MAY 13, 2024
Many insurers use similar networks for Medicaid and exchange plans, so shifting to an exchange plan is less likely to cause a lapse in coverage or abandonment of prescription drugs or maintenance medications that control chronic conditions. Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.
Expert insights. Personalized for you.
45 
Let's personalize your content